Mitochondria-target ubiquinone attenuates bleomycin-induced pulmonary fibrosis
Frontiers in Pharmacology · 04.09.2025 · 16
DOI: 10.3389/fphar.2025.1661644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.09.2025. Verfasst von Ying Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Pulmonary fibrosis arises from various etiologies, often associated with elevated levels of reactive oxygen species (ROS) stress and activation of pro-fibrotic signaling pathways. The chemotherapeutic drug bleomycin has been shown to exacerbate pulmonary fibrosis during anti-tumor treatment. Further research is needed to combat bleomycin-induced fibrosis.
Aim
This investigation aims to identify critical mediators of bleomycin-induced pulmonary fibrosis and evaluate the therapeutic potential of mitochondria-targeted ubiquinone (MitoQ) in attenuating fibrotic pathogenesis.
Methods
A bleomycin-induced pulmonary injury mouse model and fibroblast cell culture were established, followed by histopathology evaluation, molecule interaction analysis, cytokine quantification, intervention assay, and flow cytometry.
Results
We analyzed RNA-seq data from a bleomycin-induced pulmonary fibrosis mouse model and identified a network of oxidative stress-related fibrosis genes centered on Tgfb1. In fibroblast cell lines, bleomycin exposure elevated mitochondrial and cellular ROS, increased mitochondrial mass and the MDR low /MTG high cell ratio, downregulated genes linked to ROS scavenging and mitochondrial function, and upregulated transcription of pro-fibrotic molecules. MitoQ effectively reduced mitochondrial ROS, alleviated mitochondrial swelling, and restored transcription of genes involved in mitochondrial redox balance and function. Compared to conventional ubiquinone, MitoQ exhibited significantly greater antifibrotic efficacy, effectively attenuating bleomycin- and TGF-β1-induced fibroblast activation in vitro . In bleomycin-treated mice, MitoQ treatment with markedly suppressed pro-fibrotic molecule transcription and inhibited pulmonary fibrosis progression.
Conclusion
These findings not only advance our understanding of the interplay between oxidative stress and pro-fibrotic signaling in bleomycin-induced pulmonary fibrosis but also provide experimental data supporting the use of mitochondria-targeted antioxidant in the treatment of this condition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Transplantation, Key Laboratory of Organ Transplantation, Chinese Academy of Medical Sciences, Wuhan, China.
Zitieren
APA
Jiang, Y., Huang, Z., Zhou, T., Wu, M., Zhao, J., Xiong, Z., Wang, R., Chen, L., Weng, X., & Lin, L. (2025). Mitochondria-target ubiquinone attenuates bleomycin-induced pulmonary fibrosis. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1661644
Vancouver
Jiang Y, Huang Z, Zhou T, Wu M, Zhao J, Xiong Z, et al. Mitochondria-target ubiquinone attenuates bleomycin-induced pulmonary fibrosis. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1661644
BibTeX
@article{Jiang2025,
author = {Jiang, Ying and Huang, Zhenghui and Zhou, Ting and Wu, Mi and Zhao, Juan and Xiong, Zheyi and Wang, Rui and Chen, Limin and Weng, Xiufang and Lin, Lan},
title = {Mitochondria-target ubiquinone attenuates bleomycin-induced pulmonary fibrosis},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1661644}
}
EUVIMED